{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:23Z","timestamp":1790266283307,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100749","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:38:35Z","timestamp":1786556315000},"page":"100749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohort"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-3618","authenticated-orcid":false,"given":"L.G.","family":"Da Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.V.","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Lyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-8786","authenticated-orcid":false,"given":"M.I.F.M.","family":"Braguiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Mendon\u00e7a Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.L.","family":"Najman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-1891","authenticated-orcid":false,"given":"D.R.","family":"Da Rocha Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-4567","authenticated-orcid":false,"given":"M.C.","family":"Gifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.A.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Paran\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.esmorw.2026.100749_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100749_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejso.2017.04.001","article-title":"Preoperative biliary drainage in hilar cholangiocarcinoma: systematic review and meta-analysis","volume":"43","author":"Celotti","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"14","key":"10.1016\/j.esmorw.2026.100749_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100749_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100749_bib5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"10.1016\/j.esmorw.2026.100749_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100749_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/07853890.2022.2048416","article-title":"Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy","volume":"54","author":"Deng","year":"2022","journal-title":"Ann Med"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100749_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1159\/000541891","article-title":"Survival outcomes of durvalumab in combination with cisplatin and gemcitabine in advanced biliary tract cancer: real-world results from a single Italian institution","volume":"103","author":"Rimini","year":"2025","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100749_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00432-025-06239-1","article-title":"Treatment with gemcitabine\/cisplatin and durvalumab for advanced biliary tract cancer\u2014real-world data from a multicenter German patient population","volume":"151","author":"Gerhardt","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100749_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100749_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11523-024-01060-1","article-title":"Durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in biliary tract cancer: a real-world retrospective, multicenter study","volume":"19","author":"Rimini","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmorw.2026.100749_bib12","article-title":"Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes","volume":"40","author":"da Fonseca","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.esmorw.2026.100749_bib13","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"1","author":"Castelo-Branco","year":"2023","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100749_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100749_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1477-2574.2010.00197.x","article-title":"Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study","volume":"12","author":"Williams","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"14","key":"10.1016\/j.esmorw.2026.100749_bib16","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3390\/cancers13143507","article-title":"Real-world evidence on palliative gemcitabine and oxaliplatin (GemOx) combination chemotherapy in advanced biliary tract cancer","volume":"13","author":"Lagenfelt","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100749_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100749_bib18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.esmorw.2026.100749_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1497415","article-title":"Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.esmorw.2026.100749_bib20","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3390\/cancers14143483","article-title":"Association between metabolic disorders and cholangiocarcinoma: impact of a postulated risk factor with rising incidence","volume":"14","author":"Da Fonseca","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100749_bib21","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.cgh.2024.09.028","article-title":"Prevalence of chronic liver disease in cholangiocarcinoma: a meta-analysis","volume":"23","author":"Tham","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100749_bib22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1186\/s12885-021-09035-5","article-title":"Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100749_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3892\/mco.2023.2625","article-title":"Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment","volume":"18","author":"Da Fonseca","year":"2023","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100749_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"10.1016\/j.esmorw.2026.100749_bib25","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1073\/pnas.0601807103","article-title":"Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis","volume":"103","author":"Nozawa","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100749_bib26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi","year":"2011","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100749_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","article-title":"Neutrophils in cancer: heterogeneous and multifaceted","volume":"22","author":"Hedrick","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"7745","key":"10.1016\/j.esmorw.2026.100749_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmorw.2026.100749_bib29","article-title":"Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy","volume":"7","author":"Lamarca","year":"2025","journal-title":"ESMO Gastrointest Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:41:13Z","timestamp":1790264473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S2949820126000688"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100749","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100749"}}